Author:
Gerisch Michael,Schwarz Thomas,Lang Dieter,Rohde Gabriele,Reif Stefanie,Genvresse Isabelle,Reschke Susanne,van der Mey Dorina,Granvil Camille
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference24 articles.
1. Dreyling M, Morschhauser F, Bron D, Bouabdallah K, Vitolo M, Linton K, Van Den Neste E, Mappa S, Giurescu M, Childs B, Zinzani P (2014) Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3 K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma. Clin Adv Hematol Oncol 12(2 Suppl 5):14–16
2. Curran E, Smith SM (2014) Phosphoinositide 3-kinase inhibitors in lymphoma. Curr Opin Oncol 26(5):469–475
3. Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG, Keating MJ, Faia K, O’Brien S, Kutok JL, Gandhi V (2015) The phosphoinositide-3-kinase (PI3 K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3 K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia 29(9):1811–1822
4. Herman SE, Johnson AJ (2012) Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. Clin Cancer Res 18(15):4013–4018
5. Scott WJ, Hentemann MF, Rowley RB, Bull CO, Jenkins S, Bullion AM, Johnson J, Redman A, Robbins AH, Esler W, Fracasso RP, Garrison T, Hamilton M, Michels M, Wood JE, Wilkie DP, Xiao H, Levy J, Stasik E, Liu N, Schaefer M, Brands M, Lefranc J (2016) Discovery and SAR of novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3 K inhibitors: identification of copanlisib (BAY 80-6946). ChemMedChem. 11(14):1517–1530. doi: 10.1002/cmdc.201600148
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献